X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (34) 34
humans (32) 32
hematology (22) 22
oncology (18) 18
article (17) 17
child (16) 16
abridged index medicus (15) 15
male (15) 15
leukemia (14) 14
child, preschool (13) 13
female (12) 12
hemic and lymphatic diseases (12) 12
adolescent (11) 11
children (10) 10
precursor cell lymphoblastic leukemia-lymphoma - genetics (10) 10
animals (9) 9
infant (8) 8
mice (8) 8
pediatrics (8) 8
signal transduction (8) 8
adult (7) 7
cancer (7) 7
cell line, tumor (7) 7
chemotherapy (7) 7
crlf2 (7) 7
lymphoid neoplasia (7) 7
minimal residual disease (7) 7
murine xenograft models (7) 7
mutation (7) 7
research (7) 7
acute lymphoblastic leukemia (6) 6
therapy (6) 6
xenograft model antitumor assays (6) 6
young adult (6) 6
acute myeloid leukemia (5) 5
adults (5) 5
gene expression (5) 5
molecular targeted therapy (5) 5
pediatric (5) 5
philadelphia chromosome (5) 5
prognosis (5) 5
protein kinase inhibitors - pharmacology (5) 5
receptors, cytokine - genetics (5) 5
signal transduction - drug effects (5) 5
acute lymphatic leukemia (4) 4
acute lymphoblastic-leukemia (4) 4
care and treatment (4) 4
cell proliferation (4) 4
childrens oncology group (4) 4
genetic aspects (4) 4
imatinib (4) 4
immunotherapy (4) 4
janus kinases - genetics (4) 4
kinase (4) 4
kinases (4) 4
mice, inbred nod (4) 4
mtor (4) 4
mutations (4) 4
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (4) 4
signal transduction - genetics (4) 4
treatment outcome (4) 4
united states - epidemiology (4) 4
urology & nephrology (4) 4
aberrant stat5 (3) 3
analysis (3) 3
b-cell precursor (3) 3
b-progenitor (3) 3
biochemistry & molecular biology (3) 3
clinical trial (3) 3
clinical trials (3) 3
clinical trials as topic (3) 3
expression (3) 3
gemtuzumab ozogamicin (3) 3
gene mutations (3) 3
genomics (3) 3
health aspects (3) 3
hemic and immune systems (3) 3
in-vivo (3) 3
inhibition (3) 3
inhibitor (3) 3
janus kinases - antagonists & inhibitors (3) 3
kinase inhibitor therapy (3) 3
medical colleges (3) 3
mice, scid (3) 3
middle aged (3) 3
patients (3) 3
phosphorylation (3) 3
precision medicine (3) 3
precursor b-cell lymphoblastic leukemia-lymphoma - drug therapy (3) 3
precursor b-cell lymphoblastic leukemia-lymphoma - genetics (3) 3
precursor b-cell lymphoblastic leukemia-lymphoma - metabolism (3) 3
precursor cell lymphoblastic leukemia-lymphoma - diagnosis (3) 3
precursor cell lymphoblastic leukemia-lymphoma - metabolism (3) 3
precursor cell lymphoblastic leukemia-lymphoma - pathology (3) 3
precursor cell lymphoblastic leukemia-lymphoma - therapy (3) 3
protein kinase inhibitors - therapeutic use (3) 3
rapamycin (3) 3
receptor (3) 3
receptors, cytokine - metabolism (3) 3
recurrence (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Leukemia, ISSN 0887-6924, 01/2019, Volume 33, Issue 1, pp. 181 - 190
Juvenile myelomonocytic leukemia (JMML) is an uncommon myeloproliferative neoplasm driven by Ras pathway mutations and hyperactive Ras/MAPK signaling. Outcomes... 
MEK INHIBITION | ONCOLOGY | PATHWAY | ABNORMALITIES | DISEASE | ABERRANT STAT5 | CBL | HEMATOLOGY | RUXOLITINIB | CHILDREN | HYPERSENSITIVITY | TRANSPLANTATION | Induced Pluripotent Stem Cells - pathology | Protein Kinases - genetics | Induced Pluripotent Stem Cells - drug effects | Leukemia, Myelomonocytic, Juvenile - pathology | Neoplastic Stem Cells - drug effects | Humans | Protein Kinases - chemistry | Neoplastic Stem Cells - metabolism | Signal Transduction - drug effects | Neoplastic Stem Cells - pathology | Protein Kinase Inhibitors - pharmacology | Leukemia, Myelomonocytic, Juvenile - genetics | Mutation | Tumor Cells, Cultured | Leukemia, Myelomonocytic, Juvenile - drug therapy | Child | Induced Pluripotent Stem Cells - metabolism | Molecular targeted therapy | Care and treatment | Gene mutations | Leukemia in children | Innovations | Development and progression | Cellular signal transduction | Genetic aspects | Health aspects | Phosphotransferases | TOR protein | Myelomonocytic leukemia | Myeloid cells | Leukemia | Stem cell transplantation | MAP kinase | Transplantation | Rapamycin | Myeloproliferation | Hematopoietic stem cells | 1-Phosphatidylinositol 3-kinase | Hemopoiesis | Signaling | Sensitivity | Chemotherapy | Inhibitors | Stem cells | Inhibition | Children | Pluripotency | Inhibitory postsynaptic potentials | Index Medicus
Journal Article
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. 2438 - 2438
Glucocorticoids (GCs) are a component of highly effective therapy for B cell acute lymphoblastic leukemia (B-ALL), the most common childhood cancer. Although... 
Journal Article
Cancer, ISSN 0008-543X, 10/2015, Volume 121, Issue 20, pp. 3577 - 3590
Journal Article
Best Practice & Research: Clinical Haematology, ISSN 1521-6926, 2017
Abstract Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a recently identified high risk disease subtype characterized by a gene... 
Hematology, Oncology and Palliative Medicine
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 11, pp. 1005 - 1015
About 25% of young adults with ALL have Ph-like genotypes, which are associated with poor outcomes with conventional treatment. In this gene-expression study,... 
MEDICINE, GENERAL & INTERNAL | MODELS | B-CELL PRECURSOR | INHIBITOR THERAPY | IMATINIB | PEDIATRIC ACUTE LEUKEMIAS | GENE FUSION | EXPRESSION | ETV6-NTRK3 FUSION TRANSCRIPTS | CRLF2 | DELETION | Oligonucleotide Array Sequence Analysis | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - metabolism | Humans | Child, Preschool | Infant | Male | Young Adult | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Heterografts | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Adult | Female | DNA, Neoplasm - analysis | Receptors, Cytokine - metabolism | Child | Philadelphia Chromosome | Receptors, Cytokine - genetics | Signal Transduction - genetics | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - genetics | Animals | Protein Kinase Inhibitors - therapeutic use | Adolescent | Survival Analysis | Mice | Polymorphism, Single Nucleotide | Genome, Human | Protein-Tyrosine Kinases - antagonists & inhibitors | Development and progression | Care and treatment | Genetic aspects | Research | Lymphocytic leukemia | Tyrosine metabolism | Cell proliferation | Adolescence | Tyk2 protein | Leukemia | Genes | Clinical trials | Oncology | Genomes | Kinases | Cell activation | Janus kinase 2 | Xenografts | Teenagers | Children | Protein-tyrosine kinase | Age | Tyrosine | Young adults | Genomic analysis | Acute lymphatic leukemia | Stat5 protein | Lymphatic leukemia | Gene expression | Philadelphia chromosome | Interleukin 7 receptors | Thymic stromal lymphopoietin | Lymphocytes B | Cell lines | Index Medicus | Abridged Index Medicus
Journal Article
Stem Cell Research, ISSN 1873-5061, 08/2018, Volume 31, pp. 157 - 160
Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disorder of early childhood characterized by expansion of clonal myelomonocytic cells and... 
BIOTECHNOLOGY & APPLIED MICROBIOLOGY | CELL & TISSUE ENGINEERING | CELL BIOLOGY | Cellular signal transduction | Genetic aspects | Research | Gene mutations | Leukemia | Stem cells | Index Medicus
Journal Article
Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 09/2018, Volume 18, pp. S6 - S8
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 6/2009, Volume 106, Issue 23, pp. 9414 - 9418
Journal Article
Blood, ISSN 0006-4971, 10/2012, Volume 120, Issue 17, pp. 3510 - 3518
CRLF2 rearrangements, JAK1/2 point mutations, and JAK2 fusion genes have been identified in Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia... 
MAMMALIAN TARGET | RAPAMYCIN | IN-VITRO | ABERRANT STAT5 | RECEPTOR | OF-FUNCTION MUTATIONS | HEMATOLOGY | B-PROGENITOR | GENETIC ALTERATIONS | STAT5 ACTIVATION | CRLF2 | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - metabolism | TOR Serine-Threonine Kinases - metabolism | Humans | Immunoglobulins - genetics | Molecular Targeted Therapy | Immunoglobulins - metabolism | TOR Serine-Threonine Kinases - antagonists & inhibitors | Janus Kinase 1 - metabolism | STAT5 Transcription Factor - genetics | STAT5 Transcription Factor - metabolism | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | TOR Serine-Threonine Kinases - genetics | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Janus Kinase 1 - genetics | Janus Kinase 2 - metabolism | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Receptors, Cytokine - metabolism | Drug Evaluation, Preclinical | Child | Philadelphia Chromosome | Receptors, Cytokine - genetics | Janus Kinase 2 - antagonists & inhibitors | Disease Models, Animal | Pyrazoles - pharmacology | Acute Disease | Janus Kinase 2 - genetics | Survival Rate | Signal Transduction - genetics | Janus Kinase 1 - antagonists & inhibitors | Sirolimus - pharmacology | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - genetics | Xenograft Model Antitumor Assays | Animals | Signal Transduction - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Index Medicus | Abridged Index Medicus | Lymphoid Neoplasia
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 2280 - 2280
Journal Article
Blood, ISSN 0006-4971, 06/2013, Volume 121, Issue 24, pp. 4925 - 4929
Journal Article
Blood, ISSN 0006-4971, 03/2015, Volume 125, Issue 11, pp. 1759 - 1767
Journal Article